Cargando…

A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats

BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study...

Descripción completa

Detalles Bibliográficos
Autores principales: Farid, Mariam F., Abouelela, Yara S., Yasin, Noha A. E., Mousa, Mohamed R., Ibrahim, Marwa A., Prince, Abdelbary, Rizk, Hamdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563497/
https://www.ncbi.nlm.nih.gov/pubmed/36229845
http://dx.doi.org/10.1186/s41232-022-00230-w
_version_ 1784808417512128512
author Farid, Mariam F.
Abouelela, Yara S.
Yasin, Noha A. E.
Mousa, Mohamed R.
Ibrahim, Marwa A.
Prince, Abdelbary
Rizk, Hamdy
author_facet Farid, Mariam F.
Abouelela, Yara S.
Yasin, Noha A. E.
Mousa, Mohamed R.
Ibrahim, Marwa A.
Prince, Abdelbary
Rizk, Hamdy
author_sort Farid, Mariam F.
collection PubMed
description BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study was conducted on 15 adult Persian cats that were divided into three groups: control negative, control positive (ethidium bromide (EB)-treated group), and PRP co-treated group (EB-treated group intrathecally injected with PRP on day 14 post-spinal cord injury). PRP was obtained by centrifuging blood on anticoagulant citrate dextrose and activating it with red and green laser diodes. The Basso–Beattie–Bresnahan (BBB) scores were used to assess the motor function recovery on days 1, 3, 7, 14, 20, and 28 following 14 days from EB injection. Moreover, magnetic resonance imaging (MRI) analysis, histopathological investigations, transmission electron microscopy (TEM) studies, and immunohistochemical analysis were conducted, and the gene expressions of nerve growth factors (NGFs), brain-derived neurotrophic factors (BDNF), and stromal cell-derived factors (SDF) were evaluated. RESULTS: Our results indicated that PRP had a significant ameliorative effect on the motor function of the hindlimbs as early as day 20 and so on. MRI revealed that the size and intensity of the lesion were significantly reduced in the PRP co-treated group. The histopathological and TEM investigations demonstrated that the PRP co-treated group had a significant improvement in the structure and organization of the white matter, as well as a high remyelination capacity. Furthermore, a significant increase in myelin basic protein and Olig2 immunoreactivity as well as a reduction in Bax and glial fibrillar acidic protein immune markers was observed. NGFs were found to be upregulated by gene expression. CONCLUSION: As a result, we concluded that the intrathecal injection of PRP was an effective, safe, and promising method for the treatment of MS.
format Online
Article
Text
id pubmed-9563497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95634972022-10-15 A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats Farid, Mariam F. Abouelela, Yara S. Yasin, Noha A. E. Mousa, Mohamed R. Ibrahim, Marwa A. Prince, Abdelbary Rizk, Hamdy Inflamm Regen Research Article BACKGROUND: Multiple sclerosis (MS) is a progressive autoimmune demyelinating disease of the central nervous system. To date, there is no effective therapy for it. Our study aimed to determine the potential role of platelet-rich plasma (PRP) in the treatment of MS in cats. METHODS: The current study was conducted on 15 adult Persian cats that were divided into three groups: control negative, control positive (ethidium bromide (EB)-treated group), and PRP co-treated group (EB-treated group intrathecally injected with PRP on day 14 post-spinal cord injury). PRP was obtained by centrifuging blood on anticoagulant citrate dextrose and activating it with red and green laser diodes. The Basso–Beattie–Bresnahan (BBB) scores were used to assess the motor function recovery on days 1, 3, 7, 14, 20, and 28 following 14 days from EB injection. Moreover, magnetic resonance imaging (MRI) analysis, histopathological investigations, transmission electron microscopy (TEM) studies, and immunohistochemical analysis were conducted, and the gene expressions of nerve growth factors (NGFs), brain-derived neurotrophic factors (BDNF), and stromal cell-derived factors (SDF) were evaluated. RESULTS: Our results indicated that PRP had a significant ameliorative effect on the motor function of the hindlimbs as early as day 20 and so on. MRI revealed that the size and intensity of the lesion were significantly reduced in the PRP co-treated group. The histopathological and TEM investigations demonstrated that the PRP co-treated group had a significant improvement in the structure and organization of the white matter, as well as a high remyelination capacity. Furthermore, a significant increase in myelin basic protein and Olig2 immunoreactivity as well as a reduction in Bax and glial fibrillar acidic protein immune markers was observed. NGFs were found to be upregulated by gene expression. CONCLUSION: As a result, we concluded that the intrathecal injection of PRP was an effective, safe, and promising method for the treatment of MS. BioMed Central 2022-10-14 /pmc/articles/PMC9563497/ /pubmed/36229845 http://dx.doi.org/10.1186/s41232-022-00230-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Farid, Mariam F.
Abouelela, Yara S.
Yasin, Noha A. E.
Mousa, Mohamed R.
Ibrahim, Marwa A.
Prince, Abdelbary
Rizk, Hamdy
A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title_full A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title_fullStr A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title_full_unstemmed A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title_short A novel cell-free intrathecal approach with PRP for the treatment of spinal cord multiple sclerosis in cats
title_sort novel cell-free intrathecal approach with prp for the treatment of spinal cord multiple sclerosis in cats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563497/
https://www.ncbi.nlm.nih.gov/pubmed/36229845
http://dx.doi.org/10.1186/s41232-022-00230-w
work_keys_str_mv AT faridmariamf anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT abouelelayaras anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT yasinnohaae anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT mousamohamedr anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT ibrahimmarwaa anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT princeabdelbary anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT rizkhamdy anovelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT faridmariamf novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT abouelelayaras novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT yasinnohaae novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT mousamohamedr novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT ibrahimmarwaa novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT princeabdelbary novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats
AT rizkhamdy novelcellfreeintrathecalapproachwithprpforthetreatmentofspinalcordmultiplesclerosisincats